Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Inclusion Criteria:

   - Had a participant-specific batch of Idecabtagene vicleucel (ide-cel) manufactured
   intended for commercial treatment; however, the final manufactured product was
   nonconforming and did not meet commercial release criteria

   - Remanufacturing is deemed not feasible or clinically inappropriate per assessment of
   the treating physician in discussion with the participant

   - Clinically stable

Exclusion Criteria:

   - Has a hypersensitivity to the active substance or to any of the excipients

   - No experience of a significant worsening in clinical status that would, in the opinion
   of the treating physician, either increase the risk of Adverse Events associated with
   lymphodepleting chemotherapy, or exclude them from treatment with nonconforming
   Idecabtagene vicleucel (ide-cel)

   - Has any condition and/or laboratory abnormality that places the participant at
   unacceptable risk if he/she were to participate in the Expanded Access Protocol based
   on the Investigator's judgement

Other protocol-defined inclusion/exclusion criteria apply